HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2012-12-31 was 18.36K shares, a 95.66% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2012-09-30 was 7.05K shares, a 81.68% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2012-06-30 was 77.01K shares, a 93.70% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2011-12-31 was 423.48K shares.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.12M shares, a 7.08% decline from fiscal 2024.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.21M shares, a 113.66% increase from fiscal 2023.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 565.34K shares, a 28.43% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 789.87K shares, a 33.01% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 1.12M shares 10-K · filed 2026-02-17 | |
| 2024-12-31 | 1.21M shares 10-K · filed 2025-02-18 | |
| 2023-12-31 | 565.34K shares 10-K · filed 2024-02-20 | |
| 2022-12-31 | 789.87K shares 10-K · filed 2023-02-21 | |
| 2021-12-31 | 1.18M shares 10-K · filed 2022-02-22 | |
| 2020-12-31 | 4.71M shares 10-K · filed 2021-02-23 | |
| 2019-12-31 | 1.54M shares 10-K · filed 2020-02-24 | |
| 2018-12-31 | 1.49M shares 10-K · filed 2019-02-21 | |
| 2017-12-31 | 1.51M shares 10-K · filed 2019-02-21 | |
| 2016-12-31 | 413.25K shares 10-K · filed 2019-02-21 | |
| 2015-12-31 | 1.93M shares 10-K · filed 2018-02-20 | |
| 2014-12-31 | 1.43M shares 10-K · filed 2017-02-28 | |
| 2013-12-31 | 1.27M shares 10-K · filed 2016-02-29 | |
| 2012-12-31 | 18.36K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | 444.64K shares 10-K · filed 2015-03-02 |
| 2012-09-30 | 7.05K shares 10-Q · filed 2012-11-08 | |
| 2012-06-30 | 77.01K shares 10-Q · filed 2012-08-09 | |
| 2011-12-31 | 423.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | 3.14M shares 10-K · filed 2014-02-28 |
| 2011-09-30 | 38.51K shares 10-Q · filed 2012-11-08 | |
| 2011-06-30 | 1.22M shares 10-Q · filed 2012-08-09 | |
| 2010-12-31 | 479.09K shares 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |